INMB (INmune Bio) Institutional Ownership: 23.83% (As of Jul. 08, 2026)


INMB INmune Bio Inc INMB
53 GF Score
Price $1.76
GF Value $1.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is INmune Bio Institutional Ownership?

INmune Bio INMB +4.50% 53 Institutional Ownership is 23.83% as of Jul. 08, 2026. GuruFocus rates INMB with a GF Score™ of 53/100 and a GF Value™ of $1.82 (Fairly Valued). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, INmune Bio's institutional ownership is 23.83%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, INmune Bio's Insider Ownership is 17.48%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, INmune Bio's Float Percentage Of Total Shares Outstanding is 88.82%.

INmune Bio Institutional Ownership Historical Data

* Premium members only.

The historical data trend for INmune Bio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

INmune Bio Institutional Ownership Chart

INmune Bio Historical Data

The historical data trend for INmune Bio can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 13.64 13.52 13.53 13.53 13.36 13.47 13.02 12.63 12.55 10.07
INMB
53GF Score
INmune Bio Inc INMB
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

INmune Bio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 23.83% mean?
INmune Bio (INMB) has a Institutional Ownership of 23.83% as of Jul. 08, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on INmune Bio and its competitors.
Is INmune Bio's Institutional Ownership too high?
INmune Bio's current Institutional Ownership is 23.83%. Overall, INmune Bio has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's Institutional Ownership compare to GRCE and NTRB?
INmune Bio's Institutional Ownership of 23.83% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on INmune Bio and its competitors. INmune Bio's current Institutional Ownership is 23.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Fairly Valued. The stock's GF Value™ is $1.82, compared to a current price of $1.76 — trading 3.6% below its estimated fair value. The current Institutional Ownership is 23.83%. INmune Bio's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For INmune Bio (INMB), the current Institutional Ownership is 23.83% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is INmune Bio (INMB) Overvalued in 2026?

Based on GuruFocus' analysis, INmune Bio stock appears to be undervalued. The current stock price of $1.76 is trading 3.6% below its estimated GF Value™ of $1.82. GuruFocus considers INmune Bio to be Fairly Valued.

Key valuation signals for INMB:

  • Institutional Ownership: 23.83%
  • GF Value™: $1.82 vs. price of $1.76 (3.6% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

INmune Bio Business Description

Address 225 NE Mizner Boulevard, Suite 640, Boca Raton, FL, USA, 33432
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
53GF Score

Get the complete analysis for INMB

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.76
Price
$1.82
GF Value